Impact Factor 2.857
2017 JCR, Clarivate Analytics 2018

Frontiers journals are at the top of citation and impact metrics

Brief Research Report ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Psychiatry | doi: 10.3389/fpsyt.2018.00784

Feasibly, adherence and efficacy of liraglutide treatment in a sample of individuals with mood disorders and obesity

 Alessandro Cuomo1*, Simone Bolognesi1, Arianna Goracci1,  Cristina Ciuoli1, Bruno Beccarini1,  Giuseppe Maina2, Gianluca Rosso2, Edvige Facchi3, Carla Maccora1, Nicola Giordano1, Valeria Verdino1 and  Andrea Fagiolini1
  • 1Università degli Studi di Siena, Italy
  • 2Università degli Studi di Torino, Italy
  • 3Azienda USL Toscana Sud Est, Italy

Liraglutide is a once-daily injectable medication approved for the treatment of obesity. Hereby we report the feasibly, adherence and efficacy of liraglutide treatment in a sample of individuals with mood disorders and obesity.
Methods and Sample
Twenty-nine patients with Bipolar or Major Depressive Disorder received liraglutide once daily subcutaneously at a dose gradually titrated from 0.6 mg to 3 mg. All patients were obese and had previously failed multiple healthy lifestyle interventions, including exercise and diet programs. Patients’ weight was recorded before liraglutide treatment (T0) and then 1 (T1), 3 (T3), and 6 months (T6) following T0.
Mean baseline (T0) weight was 110.54 Kg (± 24.95). Compared to baseline, the percentage of weight loss was 3.37 % at T1, 7.85% at T3 and 10.20% at T6.
Thirty-one percent (n = 9) of patients had no side effects, 34.48% (n = 10) had one, 24.14% (n = 7) had two, and 10.34% (n=3) had three side effects. All 29 subjects were still on liraglutide at T1; 79.31% and 48.28% were on liraglutide at T3 and T6. No significant relationship was found between liraglutide dose and likelihood to continue the medication. No patient showed a worsening of the psychiatric condition due to liraglutide treatment. Acceptability and satisfaction with treatment were good for the 48% that completed the study.
Liraglutide treatment was efficacious, accepted and tolerated by approximately 50% of our sample, followed up for a period of 180 days. Larger, longer, controlled, prospective studies are warranted.

Keywords: liraglutide, mood, Obesity, bipolar, Depression, Depressive Disorder

Received: 22 Oct 2018; Accepted: 31 Dec 2018.

Edited by:

Virginio Salvi, ASST Fatebenefratelli Sacco, Italy

Reviewed by:

Filippo Caraci, Università degli Studi di Catania, Italy
Mario Luciano, Second University of Naples, Italy  

Copyright: © 2018 Cuomo, Bolognesi, Goracci, Ciuoli, Beccarini, Maina, Rosso, Facchi, Maccora, Giordano, Verdino and Fagiolini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Alessandro Cuomo, Università degli Studi di Siena, Siena, 53100, Tuscany, Italy,